Relationship between Systolic Ejection Time and Inflammation in End-Stage Heart Failure

被引:0
|
作者
Gutovitz, Joel [1 ]
Kutcher, Jonathan [1 ]
Cherney, David Z. [2 ]
Schiller, Yael [1 ]
Gabizon, Itzhak [3 ]
Keshet, Eran [4 ]
Rimon, Jordan [4 ]
Koren, David [5 ]
Rao, Vivek [6 ]
Grosman-Rimon, Liza [7 ]
机构
[1] Technion, Ruth & Bruce Rappaport Fac Med, Haifa, Israel
[2] Univ Toronto, Toronto Gen Hosp, Div Nephrol, Toronto, ON, Canada
[3] Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Med Ctr, Dept Cardiol, Beer Sheva, Israel
[4] York Univ, Fac Hlth, Toronto, ON, Canada
[5] Sheba Med Ctr, Dept Cardiac Surg, Tel Hashomer, Israel
[6] Univ Hlth Network, Toronto Gen Hosp, Peter Munk Cardiac Ctr, Toronto, ON, Canada
[7] Acad Coll Levinsky Wingate, Wingate Inst, IL-6937808 Netanya, Israel
关键词
end-stage heart failure; inflammation; systolic ejection time; CARDIAC MYOSIN ACTIVATOR; CHEMOKINES; RECEPTORS;
D O I
10.14423/SMJ.0000000000001801
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesSystolic ejection time (SET) and systemic inflammation are two essential indicators of heart failure (HF) progression. We aimed to evaluate the associations between SET and inflammatory mediators in end-stage HF. MethodsParticipants included 16 patients with end-stage HF recruited from the Heart Failure Clinic at Toronto General Hospital and 16 healthy individuals free of any known cardiovascular disease. SET, end systolic pressure, and levels of inflammatory mediators were documented for each patient, and a Spearman rank correlation coefficient was performed to examine differences between patients with end-stage HF and healthy controls. ResultsThe mean SET in patients with HF was shorter than in the healthy controls (283.5 +/- 34.3 ms vs 330.1 +/- 19.0 ms, P < 0.001). C-reactive protein (P = 0.001), macrophage inflammatory protein-1 beta (P = 0.041), macrophage-derived chemokine (P = 0.007), and cyclic guanosine monophosphate (P < 0.001) levels were negatively correlated with SET. The levels of other inflammatory mediators-granulocyte-stimulating factor, granulocyte-macrophage colony-stimulating factor, interleukin-8, macrophage inflammatory protein-1, macrophage inflammatory protein-1 alpha, and tumor necrosis factor alpha-were not significantly correlated with SET. ConclusionsWe found that SET was significantly lower in patients with end-stage HF compared with healthy controls and that reduced SET correlated with increased levels of several inflammatory mediators in patients with HF. By better understanding the relationship between SET and inflammation in HF, a more thorough evaluation could lead to improved risk stratification among patients with HF. Future work should investigate the roles of SET and inflammation in HF.
引用
收藏
页码:167 / 170
页数:4
相关论文
共 50 条
  • [41] Inflammation in end-stage renal failure: could it be treated?
    Stenvinkel, P
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 : 33 - 38
  • [42] End-stage heart failure: The future of heart transplant and artificial heart
    Bounader, Karl
    Flecher, Erwan
    PRESSE MEDICALE, 2024, 53 (01):
  • [43] Advanced Heart Failure and End-Stage Heart Failure: Does a Difference Exist
    Severino, Paolo
    Mather, Paul J.
    Pucci, Mariateresa
    D'Amato, Andrea
    Mariani, Marco Valerio
    Infusino, Fabio
    Birtolo, Lucia Ilaria
    Maestrini, Viviana
    Mancone, Massimo
    Fedele, Francesco
    DIAGNOSTICS, 2019, 9 (04)
  • [44] Treatment with sildenafil citrate of patients with end-stage left ventricular systolic heart failure and pulmonary hypertension
    Anagnostou, D.
    Kaldara, E.
    Sfakianaki, T.
    Kapelios, C.
    Pantsios, C.
    Repasos, C.
    Margari, Z.
    Kanakakis, J.
    Nanas, J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 292 - 293
  • [45] Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure
    Lunghetti, Stefano
    Palmerini, Elisabetta
    Urselli, Rossella
    Maffei, Silvia
    Guarino, Elisa
    Focardi, Marta
    Mondillo, Sergio
    Favilli, Roberto
    CARDIOLOGY JOURNAL, 2011, 18 (05) : 532 - 537
  • [46] When the failing, end-stage heart is not end-stage
    Renlund, Dale G.
    Kfoury, Abdallah G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (18): : 1922 - 1925
  • [47] Inotropic therapy for end-stage heart failure patients
    Toma M.
    Starling R.C.
    Current Treatment Options in Cardiovascular Medicine, 2010, 12 (5) : 409 - 419
  • [48] Peritoneal ultrafiltration in end-stage chronic heart failure
    Froehlich, Hanna
    Katus, Hugo A.
    Taeger, Tobias
    Lossnitzer, Nicole
    Grossekettler, Leonie
    Kihm, Lars
    Zeier, Martin
    Remppis, Andrew
    Frankenstein, Lutz
    Schwenger, Vedat
    CLINICAL KIDNEY JOURNAL, 2015, 8 (02): : 219 - 225
  • [49] Antiendomysial antibodies in patients with end-stage heart failure
    Prati, D
    Bardella, MT
    Peracchi, M
    Porretti, L
    Scalamogna, M
    Conte, D
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (01): : 218 - 219
  • [50] Peritoneal ultrafiltration in end-stage congestive heart failure
    Wojtaszek, Ewa
    Malyszko, Jolanta
    Matuszkiewicz-Rowinska, Joanna
    CARDIOLOGY JOURNAL, 2014, 21 (02) : 115 - 120